HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Deininger, M. W. Search for Related Content PubMed PubMed Citation Articles by Deininger, M. W. Social Bookmarking                   What's this?

Milestones and Monitoring in Patients with CML Treated with Imatinib

Correspondence: Michael Deininger, MD, Hematology and Medical Oncology, L592, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239-3098; Phone: (503) 494-1603; Fax: (503) 494-3688; Email: deininge{at}ohsu.edu

Abstract

Imatinib is the therapeutic standard for newly diagnosed patients with chronic myeloid leukemia (CML). Recent updates of the IRIS trial, a study of standard-dose imatinib in newly diagnosed chronic-phase patients treated with 400 mg imatinib daily, suggest a stabilization of progression-free survival curves at a high level, implying that the majority of patients will do well on standard therapy. However, some 20% to 30% of patients will fail on imatinib and require alternative therapies. Identification of those patients likely to fail would be desirable to allow for more intensive therapy up front. After a brief overview of the history of CML, this paper will review current recommendations for staging of CML patients at diagnosis. Next, the various tests used to monitor their response to imatinib will be discussed in the context of the currently accepted criteria for imatinib failure and suboptimal response. Last, approaches to identify high-risk patients at diagnosis will be addressed.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?